Bronchodilators modulate inflammation in chronic obstructive pulmonary disease subjects

Pierachille Santus, Carola Buccellati, Stefano Centanni, Francesca Fumagalli, Paolo Busatto, Francesco Blasi, Angelo Sala

Research output: Contribution to journalArticle

Abstract

Chronic obstructive pulmonary disease (COPD) is characterized by neutrophilic airway inflammation and oxidative stress. Leukotriene B4 (LTB4), a potent proinflammatory mediator, is synthesized by 5-lipoxygenase (5-LO), which is activated by the presence of lipid hydroperoxides resulting from oxidative stress on biological membranes. We proposed to evaluate the effect of a four week treatment with two different bronchodilators of common practice in COPD treatment, on the production of reactive oxygen species (ROS), in particular superoxide anions, and of LTB 4 by peripheral blood neutrophils obtained from COPD subjects. 24 subjects among the COPD outpatients were enrolled, and randomized to receive either formoterol (12 μg bid) or tiotropium (18 μg od). Peripheral blood neutrophils were obtained at the start and at the end of the treatment, and production of superoxide anions and of LTB4 were evaluated as previously published. The results obtained showed a decrease in the unstimulated production of superoxide by isolated neutrophils in both groups, but tiotropium only was effective in modulating the production of LTB4, while formoterol caused an increased production of superoxide in response to fMLP, when compared to values obtained before treatment. In conclusion, tiotropium showed a better antiinflammatory activity profile when compared to formoterol in a clinical setting, reducing superoxide and LTB4 production by peripheral neutrophils obtained from COPD subjects.

Original languageEnglish
Pages (from-to)343-348
Number of pages6
JournalPharmacological Research
Volume66
Issue number4
DOIs
Publication statusPublished - Oct 2012

Fingerprint

Bronchodilator Agents
Superoxides
Leukotriene B4
Chronic Obstructive Pulmonary Disease
Inflammation
Neutrophils
Oxidative Stress
Arachidonate 5-Lipoxygenase
Lipid Peroxides
Therapeutics
Reactive Oxygen Species
Anti-Inflammatory Agents
Outpatients
Membranes
Formoterol Fumarate
Tiotropium Bromide

Keywords

  • Bronchodilators
  • Chronic obstructive pulmonary disease
  • Leukotriene B
  • Neutrophils
  • Superoxide anion production

ASJC Scopus subject areas

  • Pharmacology

Cite this

Bronchodilators modulate inflammation in chronic obstructive pulmonary disease subjects. / Santus, Pierachille; Buccellati, Carola; Centanni, Stefano; Fumagalli, Francesca; Busatto, Paolo; Blasi, Francesco; Sala, Angelo.

In: Pharmacological Research, Vol. 66, No. 4, 10.2012, p. 343-348.

Research output: Contribution to journalArticle

Santus, P, Buccellati, C, Centanni, S, Fumagalli, F, Busatto, P, Blasi, F & Sala, A 2012, 'Bronchodilators modulate inflammation in chronic obstructive pulmonary disease subjects', Pharmacological Research, vol. 66, no. 4, pp. 343-348. https://doi.org/10.1016/j.phrs.2012.05.007
Santus, Pierachille ; Buccellati, Carola ; Centanni, Stefano ; Fumagalli, Francesca ; Busatto, Paolo ; Blasi, Francesco ; Sala, Angelo. / Bronchodilators modulate inflammation in chronic obstructive pulmonary disease subjects. In: Pharmacological Research. 2012 ; Vol. 66, No. 4. pp. 343-348.
@article{c2c2abc73f914a09b616ce731d55ef1c,
title = "Bronchodilators modulate inflammation in chronic obstructive pulmonary disease subjects",
abstract = "Chronic obstructive pulmonary disease (COPD) is characterized by neutrophilic airway inflammation and oxidative stress. Leukotriene B4 (LTB4), a potent proinflammatory mediator, is synthesized by 5-lipoxygenase (5-LO), which is activated by the presence of lipid hydroperoxides resulting from oxidative stress on biological membranes. We proposed to evaluate the effect of a four week treatment with two different bronchodilators of common practice in COPD treatment, on the production of reactive oxygen species (ROS), in particular superoxide anions, and of LTB 4 by peripheral blood neutrophils obtained from COPD subjects. 24 subjects among the COPD outpatients were enrolled, and randomized to receive either formoterol (12 μg bid) or tiotropium (18 μg od). Peripheral blood neutrophils were obtained at the start and at the end of the treatment, and production of superoxide anions and of LTB4 were evaluated as previously published. The results obtained showed a decrease in the unstimulated production of superoxide by isolated neutrophils in both groups, but tiotropium only was effective in modulating the production of LTB4, while formoterol caused an increased production of superoxide in response to fMLP, when compared to values obtained before treatment. In conclusion, tiotropium showed a better antiinflammatory activity profile when compared to formoterol in a clinical setting, reducing superoxide and LTB4 production by peripheral neutrophils obtained from COPD subjects.",
keywords = "Bronchodilators, Chronic obstructive pulmonary disease, Leukotriene B, Neutrophils, Superoxide anion production",
author = "Pierachille Santus and Carola Buccellati and Stefano Centanni and Francesca Fumagalli and Paolo Busatto and Francesco Blasi and Angelo Sala",
year = "2012",
month = "10",
doi = "10.1016/j.phrs.2012.05.007",
language = "English",
volume = "66",
pages = "343--348",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press",
number = "4",

}

TY - JOUR

T1 - Bronchodilators modulate inflammation in chronic obstructive pulmonary disease subjects

AU - Santus, Pierachille

AU - Buccellati, Carola

AU - Centanni, Stefano

AU - Fumagalli, Francesca

AU - Busatto, Paolo

AU - Blasi, Francesco

AU - Sala, Angelo

PY - 2012/10

Y1 - 2012/10

N2 - Chronic obstructive pulmonary disease (COPD) is characterized by neutrophilic airway inflammation and oxidative stress. Leukotriene B4 (LTB4), a potent proinflammatory mediator, is synthesized by 5-lipoxygenase (5-LO), which is activated by the presence of lipid hydroperoxides resulting from oxidative stress on biological membranes. We proposed to evaluate the effect of a four week treatment with two different bronchodilators of common practice in COPD treatment, on the production of reactive oxygen species (ROS), in particular superoxide anions, and of LTB 4 by peripheral blood neutrophils obtained from COPD subjects. 24 subjects among the COPD outpatients were enrolled, and randomized to receive either formoterol (12 μg bid) or tiotropium (18 μg od). Peripheral blood neutrophils were obtained at the start and at the end of the treatment, and production of superoxide anions and of LTB4 were evaluated as previously published. The results obtained showed a decrease in the unstimulated production of superoxide by isolated neutrophils in both groups, but tiotropium only was effective in modulating the production of LTB4, while formoterol caused an increased production of superoxide in response to fMLP, when compared to values obtained before treatment. In conclusion, tiotropium showed a better antiinflammatory activity profile when compared to formoterol in a clinical setting, reducing superoxide and LTB4 production by peripheral neutrophils obtained from COPD subjects.

AB - Chronic obstructive pulmonary disease (COPD) is characterized by neutrophilic airway inflammation and oxidative stress. Leukotriene B4 (LTB4), a potent proinflammatory mediator, is synthesized by 5-lipoxygenase (5-LO), which is activated by the presence of lipid hydroperoxides resulting from oxidative stress on biological membranes. We proposed to evaluate the effect of a four week treatment with two different bronchodilators of common practice in COPD treatment, on the production of reactive oxygen species (ROS), in particular superoxide anions, and of LTB 4 by peripheral blood neutrophils obtained from COPD subjects. 24 subjects among the COPD outpatients were enrolled, and randomized to receive either formoterol (12 μg bid) or tiotropium (18 μg od). Peripheral blood neutrophils were obtained at the start and at the end of the treatment, and production of superoxide anions and of LTB4 were evaluated as previously published. The results obtained showed a decrease in the unstimulated production of superoxide by isolated neutrophils in both groups, but tiotropium only was effective in modulating the production of LTB4, while formoterol caused an increased production of superoxide in response to fMLP, when compared to values obtained before treatment. In conclusion, tiotropium showed a better antiinflammatory activity profile when compared to formoterol in a clinical setting, reducing superoxide and LTB4 production by peripheral neutrophils obtained from COPD subjects.

KW - Bronchodilators

KW - Chronic obstructive pulmonary disease

KW - Leukotriene B

KW - Neutrophils

KW - Superoxide anion production

UR - http://www.scopus.com/inward/record.url?scp=84865009540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865009540&partnerID=8YFLogxK

U2 - 10.1016/j.phrs.2012.05.007

DO - 10.1016/j.phrs.2012.05.007

M3 - Article

C2 - 22659487

AN - SCOPUS:84865009540

VL - 66

SP - 343

EP - 348

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

IS - 4

ER -